Papillary Thyroid Cancer
Papillary Thyroid Cancer - Related Videos
03:02
Orthotopic Inoculation of Thyroid Cancer Cells into Murine Thyroid: A Procedure to Establish Orthotopic Thyroid Cancer Mouse Model
0 Views •
2023
This video describes the procedure for orthotopic inoculation of thyroid cancer cells into the thyroid gland of mouse models, which may then serve as a valuable platform to assess carcinogenesis and discover potential treatment strategies.
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
0 Views •
Cited by 2 •
2023
Here, we present a standard pipeline to obtain murine ATC tumors by spontaneous genetically engineered mouse models. Further, we present tumor dynamics and pathological information about the primary and metastasized lesions. This model will help researchers to understand tumorigenesis and facilitate drug discoveries.
04:01
Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
0 Views •
Cited by 4 •
2023
The transoral robotic total thyroidectomy and bilateral central regional lymph node dissection using three ports without axillary incision are feasible and safe for early-stage papillary thyroid carcinoma. Here we present the operative techniques of this operation.
06:22
Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
0 Views •
Cited by 14 •
2015
Murine left ventricular papillary muscle can be used to investigate cardiac contractility in vitro. This article describes in detail the isolation and experimental protocols to study cardiac contractile characteristics.
07:01
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
0 Views •
Cited by 10 •
2013
Generation of an orthotopic mouse model of anaplastic thyroid carcinoma is described here. This technique employs surgical placement of human anaplastic thyroid cancer cells into the thyroid of immunodeficient mice, thus creating a more clinically relevant setting to study disease progression as well as screen innovative therapeutic interventions.
FAQs
The disease develops when genetic alterations disrupt growth signaling in thyroid follicular cells. These changes can alter how cells regulate growth while some differentiated thyroid functions remain. This combination helps explain why a tumor can retain hormone-related cellular characteristics even as abnormal growth progresses locally.
Papillary architecture and characteristic nuclear features provide two complementary clues during tissue evaluation. The branching pattern reflects the tumor's structural organization, while nuclear findings support recognition of abnormal thyroid cells under histopathologic assessment. Together, these findings help distinguish the lesion within a diagnostic workup and inform clinical risk assessment.
Nearby cervical lymph-node spread is important because it describes disease extent beyond the thyroid and can influence risk stratification. Assessing this feature helps clinicians characterize the tumor more precisely and select management intensity, including whether additional treatments such as radioactive iodine or thyroid hormone therapy may be appropriate.
The evaluation proceeds from thyroid ultrasound to identify a lesion, followed by fine-needle aspiration, which samples cells for cytologic review. Histopathologic assessment then examines tissue architecture and characteristic nuclear features. Using these modalities together allows clinicians to connect imaging findings with cellular and structural evidence, supporting a more informed diagnosis and subsequent risk-based management.
Treatment planning is matched to tumor risk and extent. Surgery is commonly central, while radioactive iodine and thyroid hormone therapy may be added for selected patients. This approach avoids treating every case identically: disease behavior and spread help determine whether additional therapies are clinically warranted.
In medicine, studying papillary thyroid cancer supports risk stratification, personalized management, and research into targeted therapies. Risk stratification organizes patients according to tumor features and extent, while personalized management uses that information to guide treatment choices. Research can then examine how disrupted growth signaling might be addressed more selectively, linking disease biology with clinical decision-making.